TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06070480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia Group
Description: Effect of spinal anesthesia on intraocular pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Group
Description: Effect of general anesthesia with desflurane on intraocular pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Group
Description: Effect of general anesthesia with propofol on intraocular pressure
Study: NCT06405854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Children in the coordinative exercise intervention group will be encouraged to participate in sessions twice a week, each lasting 20 minutes. The foundational movement patterns tailored to the specific purpose were organized in a game format suitable for preschool-aged children. These foundational movement patterns comprise open-ended tasks progressing from simple to complex, with motor planning as a prerequisite. As the exercise intervention was game-based, the sessions were maintained as a fun, active, and social learning environment for the children. Duration of the intervention is eight weeks,
Study: NCT05191862

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol 100 mg
Description: One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol 100 mg
Description: One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: PMR 135 mg
Description: Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: PMR 135 mg
Description: Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
Study: NCT06262997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates and Kinesiotape
Description: Patients in the Pilates and Kinesiotape group will receive exactly the same Pilates training as in the Pilates group. At the end of each exercise session, Kinesio Tex Gold FP elastic tape (5 cm) will be applied with mechanical correction technique for postural correction and the tape will be renewed in each session. Waterproof, porous, adhesive, 0.5 mm thick tape will be applied to the upper trapezius.
Study: NCT04848571

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Fetal Protection Pill
Description: A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fetal Protection Pill
Description: A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa.
Study: NCT05395494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Daily oral D-cycloserine 100mg during TMS treatments (20 days).~Other Names:~Seromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Daily oral placebo during the TMS treatments (20 days).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: iTBS repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
Study: NCT05556967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immulina
Description: Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
Study: NCT06481969

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional IVF
Description: Conventional In Vitro Fertilization (IVF) procedure and standard assisted reproductive treatments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower abdominal liposuction and preparation of SVF
Description: After lower abdominal liposuction (the liposuction volume is about 100 ml), the preparation and quality inspection of SVF will be completed by a laboratory with good manufacturing practice-approved facilities immediately. The adipose tissue will be cut into pieces of about 1mm3, and the equal volume of 0.1% collagenase I will be added to digest the adipose tissue. The digestion will be terminated after 40 minutes, followed by isolation, filtration, centrifugation, resuspension and dilution to obtain the SVF suspension. The test items, including bacteria, fungi, viruses and endotoxin, will be tested, and the expression of SVF surface markers, including CD45, CD34, CD31, CD11b, CD44, CD73, CD105 and CD90, will be detected by flow cytometry to ensure the quality of the SVF suspension. After about 4 hours of quality control and detection, the SVF suspension will be transported to the operating room on ice in a sealed incubator.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian injection
Description: Under ultrasound guidance, the SVF suspension will be injected into patients' bilateral ovaries. SVF with a total amount of (1\~2)×107 cells from autologous fat tissue will be transplanted into each side of ovary. There are 3 injection points on each side of ovary, and 330±10μl SVF suspension will be administered at each point. The administration volume of each ovary will be 1ml in total. After injection, the patients will be required to lie flat for 2 hours to observe whether there would be adverse events.
Study: NCT05528666

Intervention type: OTHER
Intervention: High Efficacy Therapy (HET)
Description: HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.

Intervention type: OTHER
Intervention: Non High Efficacy Therapy (Non-HET)
Description: Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
Study: NCT04651374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko T3
Description: The device stimulates the peroneal nerve.It will be applied for the entire duration of ICU stay and replaced once every 24 hours.
Study: NCT05358782

Intervention type: DEVICE
Intervention: Dental implant positioning
Description: observational study of the effect of implant malposition

Intervention type: DEVICE
Intervention: Dental implant positioning
Description: observational study of the effect of implant malposition
Study: NCT06478940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mixtatin pulpotomy
Description: pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulpotomy
Description: pulp treatment with applying MTA
Study: NCT05754112

Intervention type: OTHER
Intervention: B lymphocyte profiling
Description: All individuals will undergo peripheral venous blood sampling and ultrasound-guided synovial tissue biopsy following a standardized procedure. B-lymphocytes will be sorted from PBMCs isolated by Ficoll gradient method using magnetic CD19-microbeads whereas tissue B-lymphocytes will be isolated from synovial tissue biopsies digested with Liberase. CD19 positive cells from PBMC will be incubated with pro-inflammatory molecules in presence or absence of Ubadacitinib. After stimulation, CD19 positive cells will be collected and processed for single cell RNA sequencing. Moreover, the impact of JAK-1 selective inhibition on B-lymphocyte cultures stimulation will be tested using ELISA method for the assessment of cytokines/chemokines production. Synovial tissue and synovial tissue B-lymphocyte subpopulations will be assessed through FACS analysis using IgD/CD27 classification. Finally, we will compare the transcriptomic profile of synovial tissue B lymphocytes from 5 subject groups.
Study: NCT06427174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca block
Description: For the group who will receive the fascia iliaca block .... After induction of the general anesthesia and before skin incision, fascia iliaca block will be performed in the patient while he is in the supine position

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: second group will receive the caudal block, we use bupivacaine 0.5 mg / kg.
Study: NCT05848232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coraFlex Catheter
Description: The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coraForce Catheter
Description: The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coraCross Catheter
Description: The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
Study: NCT05105971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
Study: NCT06468410

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: long duration Hatha Yoga
Description: 60 min of Hatha yoga for 4 weeks. Week One:Participants begin with foundational breathing and yoga practicesOn the second day, Square Breathwork is introduced to foster calm and concentration. After a warm-up, the yoga flow focuses on heart openers to increase chest and shoulder flexibility, ending with a soothing cool-down. Week Two:Advanced breathing techniques and targeted yoga flows are introduced. The second session includes Nadi Shodhana to balance the nervous system. Week Three:The focus remains on heart openers with varied breathing exercises. The second day revisits Full Yogic Breath, followed by a warm-up and another heart opener sequence, concluding with a cool-down. Week Four:The final week integrates additional breathing techniques. The last session features Kapalabhati and Suddhi Pranayama to purify and energize the body. After a warm-up, participants engage in a well-rounded yoga flow combining various poses to enhance overall fitness, concluding with a final cool-down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: short duration Hatha Yoga
Description: 30 min of Hatha yoga for 4 weeks .

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: participants will receive information about physical activity guidelines but will not engage in any structured yoga exercise during the study period.
Study: NCT05441046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab
Description: genakumab plus tislelizumab 200 mg
Study: NCT05105971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
Study: NCT05149209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical restoration
Description: A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical restoration
Description: A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.
Study: NCT05603351

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetic resonance
Description: biparametric MRI with protocol including anatomical T2 sequence and diffusion-weighted images (DWI), according to the standards

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum PSA examination
Description: testing of prostate-specific antigen (PSA) in serum
Study: NCT05105971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
Study: NCT06012604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic mesenchymal stromal stem cells
Description: mesenchymal stromal stem cells injection under ultrasound guidance into parotid and submandibular glands
Study: NCT05429684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (6mg/Kg, iv.drip, d1, q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (6mg/Kg, iv.drip, d1, q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (6mg/Kg, iv.drip, d1, q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (6mg/Kg, iv.drip, d1, q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (6mg/Kg, iv.drip, d1, q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Patuzumab (420mg iv.drip, d1,q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Patuzumab (420mg iv.drip, d1,q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-paclitaxel (200mg iv.drip, d1,d8, q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-paclitaxel (200mg iv.drip, d1,d8, q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-paclitaxel (200mg iv.drip, d1,d8, q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyroltinib (400mg po qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (1250mg/m2, po, bid, d1-d14, q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: T-DM1(3.6mg/Kg, iv.drip, d1, q3w)
Study: NCT05045963

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical record reviewed
Study: NCT05429684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus (4mg, po, qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitor
Description: Palbociclib (125mg, po, qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI
Description: Letrozole (2.5mg, qd).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Cindilimab (200mg, iv.drip, d1, q3w)
Study: NCT05587543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PK Blood Collection
Description: All subjects were subjected to PK blood sampling as prescribed by the protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PK Blood Collection
Description: All subjects were subjected to PK blood sampling as prescribed by the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR
Description: Target A positive subjects will receive CAR-T cell therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCR
Description: Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.
Study: NCT05596240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Dry Needling
Description: Streitberger Placebo-needles (Asia-med, Las Vegas, NV) will be used to perform the intervention for participants in the sham DN group. These needles have been reported to be indistinguishable from real needles. The device consists of a plastic tube with a blunted tip needle that allows for the sensation of a prick without penetrating the skin. The sham needle produces a sensation, which causes the participant to feel as if the needle enters the skin, while maintaining similar patient-therapist contact time and total intervention time.
Study: NCT05725525

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Remote PCIT augmented with wearable devices
Description: Participants will be enrolled in remote PCIT and be asked to wear a Garmin watch throughout the course of the study in order to measure biometric fluctuations
Study: NCT05264675

Intervention type: PROCEDURE
Intervention: primary suture
Description: Primary suture of the EPL-tendon

Intervention type: PROCEDURE
Intervention: EIP-transfer
Description: transfer of the EIP-tendon to the EPL-tendon
Study: NCT04785807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post traumatic, Anxiety and depression evaluation
Description: Family member of person or trust of patient who had a limitation or discontinuation of treatments will be identified and asked to fulfilled a hospitalized anxiety and depression scale and the revised Impact Event scale 7 and 30 days after the limitation or discontinuation of treatments announcement
Study: NCT06041828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Photodynamic antibacterial dual-light device with a marker substance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene
Description: Standard oral hygiene instructions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene
Description: Standard oral hygiene instructions
Study: NCT06132997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopy procedure
Description: is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopy procedure
Description: is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube thoracostomy
Description: Insert chest intercostal tube without thoracoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube thoracostomy
Description: Insert chest intercostal tube without thoracoscopy
Study: NCT04367935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline tablets 400mg three times daily for 2 months
Study: NCT05303974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided joint injection
Description: The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided joint injection
Description: The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided joint injection
Description: The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.
Study: NCT05431751

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Algae
Description: Whole Euglena gracilis algae, produced by proprietary fermentation.